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Polygenic risk score opportunities for early detection
and prevention strategies in endometrial cancer
Tracy A. O’Mara1 and Emma J. Crosbie 2,3
Recent large-scale genetic studies, particularly genome-wide association studies (GWAS), have emphasised the importance of
common genetic variation in endometrial cancer susceptibility. Although each of these variants only confer modest effects on
endometrial cancer risk, together they are likely to explain a substantial amount of the familial relative risk of the disease. Therefore,
methods to combine genetic risk variants, such as polygenic risk scores (PRS) have gained traction as an attractive method for
individualised risk prediction and management. Here, we discuss the benefits of a PRS for endometrial cancer and considerations
required for clinical implementation.
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Endometrial cancer is the most commonly diagnosed gynaecolo-
gical malignancy in the developed world.1 It is clear that
endometrial cancer has a hereditary component, with studies
estimating that women with a first-degree relative with endo-
metrial cancer have a 2/3-fold increased risk of developing the
disease themselves.2 A proportion of this can be explained by rare,
pathogenic variants in high-risk genes, mainly the mismatch repair
(MMR) genes associated with Lynch syndrome,3 while common
genetic variants (i.e. polygenic factors) are estimated to account
for around 28% of the familial risk of endometrial cancer.4
Significant progress has been made in our understanding of the
role of common genetic variation in endometrial cancer suscept-
ibility, with a recent review by Bafligil et al. highlighting genetic
variants detected by genome-wide association study (GWAS) as
showing greater reliability than those detected by candidate gene
studies.5 GWAS studies for endometrial cancer have been largely
driven by the international Endometrial Cancer Association
Consortium (ECAC) and have identified 16 genetic regions
associated with risk of this disease.4,6 Collectively, these regions
explain approximately one quarter (~7%) of the polygenic risk of
endometrial cancer.6
Individually, genetic variants identified by GWAS have a marginal
effect on disease risk (odd ratios typically between 0.8 and 1.2).
However, assessing genetic variants’ combined effect by polygenic
risk score (PRS) has gained traction as a means to stratify patients
into high- and low-risk strata. Theoretical PRS calculations by Bafligil
et al., using 24 curated endometrial cancer genetic risk variants,
predicted a 3.16-fold difference in endometrial cancer risk between
women in the top 1% of the PRS distribution compared with the
mean PRS.5
The results from Bafligil et al.5 are exciting and support further
research into the development of a PRS for endometrial cancer.
Studies to assess risk stratification of women in independent
cohorts are currently underway. This work will refine the number
of variants to include in PRS calculations for improved accuracy.
Additionally, the integration of an endometrial cancer PRS with
other known endometrial cancer risk factors (e.g. obesity) should
further improve risk stratification accuracy.
The overall survival for endometrial cancer is similar to that
observed for breast cancer (82% survival over 5 years).7 However,
outcome is significantly worse for women with late stage disease
(16–45% 5-year survival).7 Unlike many cancers, the incidence and
mortality rates of endometrial cancer are increasing, probably due
to the rising rates of obesity, sedentary lifestyles and the ageing
population. These increases are projected to continue over the
next decade, providing impetus for the development of early
detection and disease prevention.8
An endometrial cancer PRS could potentially provide personalised
risk information for a considerable proportion of women.
Population-based risk management strategies could identify women
at high risk of developing endometrial cancer for screening and
allow for less monitoring for women with a low PRS.9 This would
also provide opportunities for targeted interventions for high-risk
women such as progestin (or progestin-based alternative) treatment
and/or bariatric surgery, which have demonstrated remarkable
success at endometrial cancer risk reduction.10 However, while the
use of a PRS would provide access to personalised risk information
to a wider group of women, careful consideration for implementa-
tion of the PRS into population-based screening will be required and
large-scale studies necessary to assess its clinical impact.
The progress of PRS for endometrial cancer should be
considered in the light of two major limitations. Firstly, GWAS
for endometrial cancer to date have been unselected for subtype
and consequently, the results from these studies are largely driven
by the more common endometrioid endometrial cancer cases.
Indeed, there are currently no genetic risk variants reliably
associated with any non-endometrioid endometrial cancer
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subtype.4,6 This is an area requiring focus, given non-endometrioid
subtypes of endometrial cancer are associated with poorer patient
outcomes; these patients would greatly benefit from the early
detection and preventative opportunities a PRS could provide.
Secondly, all endometrial cancer genetic risk variants identified
to date were discovered using European corhorts.4,6 Thus, PRS
constructed using these variants may not provide suitable risk
stratification in women of other ethnicities, reinforcing the need
for future endometrial cancer GWAS to be performed in diverse
population sets.
Despite these limitations, the potential benefits offered by a PRS
to provide personalised risk assessment for endometrial cancer are
exciting. While opportunities for population-based screening are
evident, integration of a PRS could also be used in the familial
cancer setting, to predict which women from Lynch Syndrome
families are most likely to develop endometrial cancer and would
benefit from prevention interventions. Larger GWAS meta-
analyses planned by the ECAC will not only identify new genetic
risk regions for endometrial cancer but also refine risk estimates
associated with known regions, thus improving prediction
accuracy of constructed PRS. It is likely that maximal benefit of
an endometrial cancer PRS will be in combination with lifestyle
and clinical measures.9 Assessment of the improved predictive
value of these integrated risk models will be imperative in the
development of risk stratification and screening programmes for
endometrial cancer.9 “Is it possible to develop a personalised score
that reflects a woman’s individual risk of developing endometrial
cancer” emerged as the most important endometrial cancer
research priority in a recently completed James Lind Alliance
Priority Setting Partnership.11 Its endorsement by patients, the
public and healthcare professionals supports the urgent need for a
robust, clinically tractable endometrial cancer risk prediction
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